Company intelligence / Profile preview

EyeVision Pharma

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

EyeVision Pharma is developing novel eyedrop therapies using an artificial intelligence-driven platform to identify effective drug combinations that inhibit axial elongation of the eye—the root cause of myopia. The company leverages proprietary linker chemistry and pro-moiety libraries to create new chemical entities with improved ocular delivery. Their approach aims to address limitations seen with current treatments like low-dose atropine, which have shown disappointing efficacy in recent studies. No clinical results are available yet as programs are preclinical.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeCombination therapyProdrug conjugates
Industry: Biotech

Partnerships

Seeking investment and partnering opportunities; no major partnerships announced yet.

Beyond the preview

Go deeper on EyeVision Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeVision Pharma.

Explore the full profile